Dozens of trials on HIV ground to a halt in February after US President Donald Trump abruptly pulled crucial funding.

Gain key insights from Gilead Sciences' Q1 2025 earnings call, featuring strong HIV sales, Lenacapavir launch updates, and market trends shaping ...

O'Day emphasized the upcoming FDA decision for Lenacapavir for PrEP, expected by June 19, 2025, and its potential launch in the U.S. shortly thereafter. This is one of nine HIV product launches ...

GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the ...

An ambitious plan to stop the global threat of AIDS has been derailed. But many are hopeful that progress can be salvaged.

Why it matters: Gilead's stable outlook amid two key uncertainties—potential pharmaceutical tariffs and the upcoming launch of lenacapavir for the prevention of HIV—was reassuring. Gilead has ...

The FDA is expected to decide on treatments for bullous pemphigoid, hereditary angioedema, HIV PrEP, ovarian cancer, and RSV.

We were getting there.” A pharmacist holds a vial of lenacapavir, an injectable drug to treat HIV, at the Desmond Tutu Health Foundation’s Masiphumelele Research Site, in Cape Town ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

(Nasdaq: GILD) announced today its first quarter 2025 results of operations. "Gilead had a strong start to the year driven by ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...